China to approve imports of hemophilia treatment

09/20/2007 | China Daily (Beijing)

China plans to approve imports of a Bayer Healthcare recombinant-clotting factor to ease the country's current medication shortage for hemophilia patients. Officials stressed they are not easing an existing ban on imported blood and plasma-derived products because the treatment is not made from human plasma.

View Full Article in:

China Daily (Beijing)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC